Trial
NCT03958383
IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Wisconsin, Madison
Collaborators
National Cancer Institute (NCI); Bristol-Myers Squibb; AnYxis Immuno-Oncology GmbH; Provenance Biopharmaceuticals
Condition
Melanoma
Intervention
hu14.18-IL2
Why stopped
Administrative
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-03